AUPH - Company ID 0001600620
The table below shows Aurinia Pharmaceuticals Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Revenue | $83.70M | $83.22M | $77.70M | $77.11M | $73.47M | $70.01M |
| Cost of revenue | $8.31M | $6.55M | $6.50M | - | $8.18M | $7.12M |
| Gross profit | - | - | - | - | - | - |
| R&D | $16.61M | $13.05M | $7.47M | - | $8.44M | $7.43M |
Aurinia Pharmaceuticals Inc. reported annual revenue of $283.06M for fiscal year 2025. That is up 20.4% from $235.13M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $463.00K (FY 2018) to $283.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $24.68M |
| $23.51M |
| $22.03M |
| - |
| $26.18M |
| $26.02M |
| Operating income | $35.36M | $46.34M | $41.42M | $33.24M | $29.75M | $20.08M |
| Income tax | $7.01M | $11.37M | $9.57M | - | $411.00K | $643.00K |
| Net income | $31.70M | $37.41M | $34.35M | $210.79M | $31.55M | $21.51M |
| EPS (diluted) | $0.23 | $0.28 | $0.25 | $1.53 | $0.23 | $0.16 |